Antithrombotic effects of low molecular weight heparin (FR-860) in rabbits.
- 1 January 1989
- journal article
- research article
- Published by Japanese Pharmacological Society in Folia Pharmacologica Japonica
- Vol. 94 (4) , 237-242
- https://doi.org/10.1254/fpj.94.237
Abstract
Effects of low molecular weight heparin (FR-860) were investigated on the arterio-venous (A-V) shunt model and on the in vitro blood coagulation system compared to conventional unfractionated heparin (UF-heparin) in rabbits. In the A-V shunt model, FR-860 (12.5 .apprx. 50 U/kg, i.v.) and UF-herapin (25 and 50 U/kg, i.v.) dose-related inhibited thrombotic formation in the tube of the A-V shunt at 30 min after starting blood circulation. Both FR-860 and UF-herapin dose-relatedly increased the anti-F.Xa activity at 5 min after starting blood circulation. However, FR-860 showed weaker effects in a prolongation of the aPTT, PT and thrombin time than UF-heparin in the A-V shunt model. Neither FR-860 nor UF-heparin had any influence on platelet aggregation. FR-860 also had a weaker effect in the prolongation of the plasma recalcification time, aPTT and PT than UF-heparin in vitro. Fr-860 showed equipotent efficacy on the anti-F.Xa activity and had weak antithrombin activity compared to that of UF-heparin in vitro. These results suggest that the antithrombotic effect of FR-860 mainly depends on its anti-F.Xa activity but not on the antithrombin activity. Therefore, FR-860 is more efficient and lower in bleeding risk than UF-heparin in hemodialysis and thrombotic disorders.This publication has 10 references indexed in Scilit:
- Pharmacokinetics of Heparin and Low Molecular Weight Heparin Fragment (Fragmin®) in Rabbits with Impaired Renal or Metabolic ClearanceThrombosis and Haemostasis, 1987
- Localization of the structural difference between bovine blood coagulation factors X1 and X2 to tyrosine 18 in the activation peptide.Journal of Biological Chemistry, 1986
- A Method for Systematic Purification from Bovine Plasma of Six Vitamin K-Dependent Coagulation Factors: Prothrombin, Factor X, Factor IX, Protein S, Protein C, and Protein Z1The Journal of Biochemistry, 1985
- Heparin Treatment of Deep Venous Thrombosis in 280 Patients: Symptoms Related to DosageActa Medica Scandinavica, 1984
- Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivoThrombosis Research, 1982
- THE RELATIONSHIP BETWEEN THE HEMORRHAGIC AND ANTITHROMBOTIC PROPERTIES OF LOW-MOLECULAR WEIGHT HEPARIN IN RABBITS1982
- The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombinBiochemical Journal, 1981
- Hemorrhage during High-Risk Hemodialysis Using Controlled HeparinizationNephron, 1981
- Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasmaThrombosis Research, 1979
- Minimal Intermittent Heparinization during HemodialysisNephron, 1979